Research programme: psoriasis therapies - GroPep

Drug Profile

Research programme: psoriasis therapies - GroPep

Alternative Names: pp 0102; PP-0102

Latest Information Update: 04 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northern Sydney Health
  • Class Peptides
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 04 Feb 2011 Discontinued - Preclinical for Psoriasis in Australia (Topical)
  • 21 Mar 2006 PP 0102 is available for licensing (
  • 31 Dec 2003 Preclinical trials in Skin disorders in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top